The capacity crunch in biopharma is a location problem
BioPharma DiveMay 11, 2026
biopharmacell-therapygene-therapyscalabilitymanufacturing
The biopharma industry is facing a capacity crunch primarily due to geographical limitations in the production of cell and gene therapies. The article discusses how the availability of 'ready-now' locations can significantly impact the scalability of these therapies, suggesting that strategic site selection is crucial for overcoming current production challenges.